Sydney, NSW, 9 November, 2006 – Giaconda Limited (ASX: GIA), today announced that the European Patent Office has granted its patent for the combination of rifabutin, amoxicillin and a proton pump inhibitor for the treatment of resistant Helicobacter Pylori infection. This patent is part of a wider PCT application (priority date 30 April 1998) that has already been granted in Australia and the United States.
